Market Size and Growth

The global lysosomal storage disorders (LSDs) market reached US$ 9.68 Billion in 2023 and is projected to rise to US$ 18.18 Billion by 2033, growing at a CAGR of 6.6% during 2025-2033. The market growth is driven by increasing prevalence of rare genetic disorders, rising awareness about early diagnosis, and advancements in enzyme replacement and gene therapies. Expanding healthcare infrastructure and supportive government initiatives further fuel the demand. Additionally, ongoing research and development of novel treatments contribute to the market's robust expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/lysosomal-storage-disorders-market?ram

Key Developments:

United States: Lysosomal Storage Disorders

✅ October 2025: The FDA granted accelerated approval for a novel gene therapy targeting Fabry disease, marking a significant advancement in the treatment of this lysosomal storage disorder.

✅ October 2025: The National Institutes of Health (NIH) launched a multi-center clinical trial to evaluate the efficacy of enzyme replacement therapies (ERTs) in treating late-onset Pompe disease, aiming to improve patient outcomes through early intervention.

✅ October 2025: A collaborative research initiative between U.S. biotech firms and academic institutions resulted in the development of a next-generation ERT for Gaucher disease, designed to enhance tissue penetration and reduce immunogenic responses.

✅ August 2025: Texas expanded its newborn screening program to include four new lysosomal storage disorders, enabling early diagnosis and intervention for affected infants.

Japan: Lysosomal Storage Disorders

✅ October 2025: Japan's Ministry of Health, Labour and Welfare approved the use of a new ERT for Mucopolysaccharidosis type I (MPS I), expanding treatment options for patients with this rare genetic disorder.

✅ October 2025: A Japanese pharmaceutical company initiated a Phase III clinical trial for a gene therapy targeting Fabry disease, aiming to provide a one-time treatment option for patients with this condition.

✅ October 2025: The Japanese government announced increased funding for research into lysosomal storage disorders, focusing on the development of novel therapies and improving diagnostic capabilities.

Recent Mergers and Acquisitions:

United States: Lysosomal Storage Disorders (LSDs) M&A

United States: Lysosomal Storage Disorders M&A

✅ October 2025: Amicus Therapeutics acquired a U.S.-based biotech firm specializing in gene therapies for lysosomal storage disorders, strengthening its pipeline in this therapeutic area.

✅ October 2025: Sanofi Genzyme completed the acquisition of a company focused on developing small molecule therapies for Gaucher disease, enhancing its portfolio of LSD treatments.

Japan: Lysosomal Storage Disorders M&A

✅ October 2025: A Japanese pharmaceutical company merged with a U.S.-based biotech firm to jointly develop and commercialize enzyme replacement therapies for lysosomal storage disorders, aiming to expand their global reach.

Key Players:

=> Sanofi Genzyme, Shire, Alexion Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Amicus Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., and Ultragenyx Pharmaceutical Inc.

Growth Forecast Projected:

The Global Lysosomal Storage Disorders (LSDs) Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Lysosomal Storage Disorders (LSDs) Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=lysosomal-storage-disorders-market?ram

Key Segments:

➥ By Disease Type: Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis (MPS), Niemann-Pick Disease, Others

➥ By Treatment Type: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Stem Cell Transplantation, Chaperone Therapy, Gene Therapy (Emerging), Supportive Treatment

➥ By Route of Administration: Intravenous, Oral, Others

➥ By End User: Hospitals, Specialty Clinics, Research Institutes, Home Healthcare

Regional Analysis for Lysosomal Storage Disorders (LSDs) Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Contact Us -

Company Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.